Therapeutic Asset Ratings

119 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
DEXAMETHASONE Neoplasms	Hellenic Society of Hematology	P3	BB (66)
Carboplatin Neoplasms	Bristol-Myers Squibb	P3	BB (64)
Cetuximab Neoplasms	Mirati Therapeutics Inc.	P4	B (63)
PREDNISONE TABLETS Neoplasms	The First Affiliated Hospital of Soochow University	P3	B (62)
Letrozole Neoplasms	TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)	P2	B (61)
Denosumab Neoplasms	Alliance for Clinical Trials in Oncology	P4	B (60)
ALECTINIB Neoplasms	Cancer Research UK	P3	B (60)
cc-5013 Neoplasms	Hellenic Society of Hematology	P3	B (60)
Favezelimab Neoplasms	Merck Sharp & Dohme LLC	P3	B (60)
Vinorelbine Neoplasms	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	P3	B (60)
FULVESTRANT Neoplasms	Terremoto Biosciences Inc.	P2/3	B (60)
Mitoxantrone Neoplasms	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P3	B (59)
Cobimetinib Neoplasms	Helsinki University Central Hospital	P2	B (59)
Dostarlimab Neoplasms	GlaxoSmithKline	P2	B (58)
Nelistotug (immunoglobulin G1-kappa, anti-[Homo sapiens CD96 (T cell activation increased late expression, TACTILE, T-cell surface protein tactile)], Homo sapiens monoclonal antibody) Neoplasms	GlaxoSmithKline	P2	B (58)
Niraparib Neoplasms	GlaxoSmithKline	P2	B (58)
Axitinib Neoplasms	Yonsei University	P3	B (57)
Ezabenlimab Neoplasms	Boehringer Ingelheim	P2	B (57)
Neratinib Neoplasms	Memorial Sloan Kettering Cancer Center	P2	B (57)
Fluciclovine Neoplasms	VA Greater Los Angeles Healthcare System	P4	B (56)
Gdc-0068 Neoplasms	Hoffmann-La Roche	P2	B (56)
Belrestotug Neoplasms	GlaxoSmithKline	P2	CCC (55)
Regorafenib Neoplasms	Helsinki University Central Hospital	P2	CCC (55)
Bendamustine Neoplasms	UNC Lineberger Comprehensive Cancer Center	P3	CCC (54)
Microbubble Neoplasms	NaviFUS Corporation	P3	CCC (52)

Showing 1 to 25 of 119 assets

PreviousPage 1 of 5Next